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Background: Rhabdomyosarcoma (RMS) is a highly malignant tumour accounting for nearly half of soft tissue
sarcomas in children. MicroRNAs (miRNAs) represent a class of short, non-coding, regulatory RNAs which play a critical
role in different cellular processes. Altered miRNA levels have been reported in human cancers, including RMS.
Methods: Using deep sequencing technology, a total of 685 miRNAs were investigated in a group of alveolar RMSs
(ARMSs), embryonal RMSs (ERMSs) as well as in normal skeletal muscle (NSM). Q-PCR, MTT, cytofluorimetry, migration
assay, western blot and immunofluorescence experiments were carried out to determine the role of miR-378a-3p in
cancer cell growth, apoptosis, migration and differentiation. Bioinformatics pipelines were used for miRNA target
prediction and clustering analysis.
Results: Ninety-seven miRNAs were significantly deregulated in ARMS and ERMS when compared to NSM. MiR-378
family members were dramatically decreased in RMS tumour tissue and cell lines. Interestingly, members of the
miR-378 family presented as a possible target the insulin-like growth factor receptor 1 (IGF1R), a key signalling molecule
in RMS. MiR-378a-3p over-expression in an RMS-derived cell line suppressed IGF1R expression and affected
phosphorylated-Akt protein levels. Ectopic expression of miR-378a-3p caused significant changes in apoptosis, cell
migration, cytoskeleton organization as well as a modulation of the muscular markers MyoD1, MyoR, desmin and MyHC.
In addition, DNA demethylation by 5-aza-2′-deoxycytidine (5-aza-dC) was able to up-regulate miR-378a-3p levels with
a concomitant induction of apoptosis, decrease in cell viability and cell cycle arrest in G2-phase. Cells treated with
5-aza-dC clearly changed their morphology and expressed moderate levels of MyHC.
Conclusions: MiR-378a-3p may function as a tumour suppressor in RMS and the restoration of its expression would be
of therapeutic benefit in RMS. Furthermore, the role of epigenetic modifications in RMS deserves further investigations.
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Rhabdomyosarcoma (RMS) is the most common soft tis-
sue sarcoma in childhood [1], representing approxi-
mately 50% of all sarcomas in children aged 0–14 years
and 4-5% of malignant solid tumours in the paediatric
population. The two major histological subtypes, alveolar* Correspondence: francesca.megiorni@uniroma1.it
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sarcoma (ERMS), have distinct clinical features and out-
comes. ERMSs are more frequent (~80% of cases) and
generally affect younger children (0–4 years); they occur
more commonly in the neck, head and genito-urinary
tract [2]. As the name implies, tumour cells resemble
embryonal skeletal muscle cells. ARMSs (~20% of cases)
usually present throughout childhood, typically originat-
ing in the limbs and trunk, often with regional or meta-
static lymph node involvement already at diagnosis, and
carry a significantly worse outcome [2,3]. ARMS is soal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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alveoli.
The role of genetic factors in the development of RMS
has been confirmed by several recent epidemiological
observations and advances in molecular genetics. Al-
though the majority of RMS cases are sporadic, i.e. not
associated with hereditary syndromes, a small propor-
tion are linked to congenital anomalies, e.g. Beckwith-
Wiedemann syndrome, or are associated with particular
familial syndromes, such as neurofibromatosis type I and
Li-Fraumeni syndrome [4-6]. ARMS and ERMS are both
characterised by particular genetic alterations that are
likely to play a decisive role in cancer pathogenesis.
Eighty percent of ARMS tumours have either t(2;13)
(q35,q14) or t(1;13)(p36;q14) chromosomal transloca-
tions, which generate PAX3-FOXO1 and PAX7-FOXO1
fusion proteins, respectively [7]. However, constitutive
expression of PAX3/7-FOXO1 chimeric genes is not suf-
ficient to induce RMS development in transgenic ani-
mals [8,9]. Loss of heterozygosity of the short arm of
chromosome 11 (11p15.5), with over-expression of the
insulin-like growth factor II, is often associated with
ERMS [10]. However, although several tumour causative
genes have been identified, a detailed understanding of
the molecular mechanisms underlying RMS develop-
ment has not yet been achieved.
Recent studies have suggested that microRNAs (miR-
NAs) may play an essential role in RMS [11,12]. MiRNAs
are a class of conserved, short, non-coding molecules
which regulate gene expression through binding to non-
perfect complementary sequences at the 3′-untranslated
regions (UTRs) of target messenger RNAs (mRNAs),
resulting in translational repression [13]. Several pre-
miRNAs stem-loops are processed to produce two mature
and functional miRNAs, designated with the suffix “-3p”
or “-5p,” depending on the originating hairpin arm [14]. It
has been predicted that about one-third of all mammalian
genes are targeted by miRNAs [15,16]. Deregulation of
miRNA expression is associated with various cancers and
many studies indicate that miRNAs may act either as
oncogenes or tumour suppressors [17-19], controlling
key processes in tumorigenesis, such as tumour initi-
ation, progression and metastatic spread. An increas-
ing number of miRNAs, such as miR-1, miR-133a,
miR-200c, miR-206, miR-214 and miR-9*, have been
identified to have a role in RMS [11,20-24], as recently
summarized by Novak et al. [12].
Epigenetic DNA changes, such as DNA promoter
hypermethylation and histone modifications, have crit-
ical roles in chromatin remodelling and general regula-
tion of gene expression in mammalian development and
human diseases [25]. In particular, DNA methylation of
CpG islands in promoter regions has been correlated
with silencing of tumour suppressor genes and othertumour-related genes, and it has been recognised as a
crucial component of the mechanism underlying cancer
development [26]. DNA methylation-associated silencing
of miRNAs in different human tumours, including RMS,
has also been reported [27,28].
In this study, deep sequencing technology was utilised
to quantify the absolute abundance of miRNAs in ARMS
and ERMS tumours as well as in normal skeletal muscle
(NSM), and to identify an RMS-specific miRNA expression
pattern. The majority of miRNAs were found to be down-
regulated, as predicted. Interestingly, miR-378a/b/c/d/e/f/
h/i molecules, belonging to a large family of evolutionary
conserved miRNAs, were strongly under-represented
in ARMS and ERMS tumours in comparison to NSM.
Transient transfection of miR-378a-3p in an ARMS-
derived cell line (RH30) induced apoptosis and decreased
viability/proliferation by repressing the IGF1R/AKT path-
way. Importantly, elevated levels of miR-378a-3p impaired
RH30 cell migration and promoted myogenic differenti-
ation. Demonstration that epigenetic modifications may be
involved in RMS tumourigenesis was achieved by restoring
miR-378a-3p levels. In addition, 5-aza-2′-deoxycytidine
(5-aza-dC) treatment induced apoptosis, cell cycle arrest in
G2 phase and decreased cell viability compared to un-
treated RH30 cells. Interestingly, RH30 5-aza-dC-treated
cells changed their morphology and expressed muscle dif-
ferentiation markers, partially overlapping the effect of
miR-378a-3p transfection.
Taken together, these data provide the first evidence
for an anti-tumour activity of miR-378a-3p in RMS, sug-
gesting that this miRNA could be a potential therapeutic
target in RMS. Furthermore, the importance of epigen-
etic regulation in RMS was confirmed, which may have
important clinical implications in this malignancy.
Methods
Patient clinical and tumour histopathological
characteristics
Fifteen RMS tumour samples, 7 ARMSs and 8 ERMSs,
were obtained at diagnosis before any treatment from
children admitted to the Department of Paediatrics and
Infantile Neuropsychiatry at “Sapienza” University, and
to the Department of Oncology at Alder Hey Children’s
NHS Trust, Liverpool. Histopathological diagnosis was
confirmed using immunohistochemistry. All 7 ARMS
were investigated for PAX3/7-FOXO1 translocations
using standard FISH analysis: 5 tumours were PAX3-
FOXO1–positive, 1 was PAX7-FOXO1–positive and 1
was fusion-negative. Patients were grouped according
to the Intergroup Rhabdomyosarcoma Study (IRS)
postsurgical grouping system [29]. Details of the patients
are described in Table 1. ARMS1-2-3-4 and ERMS1-2-3-4
tumour samples were used for deep sequencing study.
Institutional written informed consent was obtained from
Table 1 Clinico-pathological features of the analysed
tumour cases
Case Histology Fusion status Primary site Clinical stage
ARMS1* alveolar PAX3 trunk III
ARMS2* alveolar PAX3 extremity III
ARMS3* alveolar negative trunk II
ARMS4* alveolar PAX7 uterus-vagina III
ARMS7 alveolar PAX3 extremity IV
ARMS36 alveolar PAX3 trunk III
ARMS37 alveolar PAX3 uterus-vagina II
ERMS1* embryonal n.a. retroperitoneum III
ERMS2* embryonal n.a. bladder-prostate III
ERMS3* embryonal n.a. bladder-prostate III
ERMS4* embryonal n.a. trunk III
ERMS12 embryonal n.a. bladder-prostate III
ERMS21 embryonal n.a. retroperitoneum III
ERMS23 embryonal n.a. uterus-vagina II
ERMS27 embryonal n.a. extremity I
Variables were categorized as follows: histological subtype, embryonal versus
alveolar; gene fusion status; primary site and clinical stage. Fusion status PAX3:
PAX3-FOXO1–positive; PAX7: PAX7-FOXO1–positive ; n.a. - not applicable. The
symbol * indicates samples used for deep sequencing analysis.
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went ethical review and approval according to the local
institutional guidelines (Policlinico Umberto I’s Ethics
Committee and Alder Hey Children’s NHS Foundation
Trust Ethics Committee). Control RNA was extracted
from normal skeletal muscle (NSM) obtained from eight
children undergoing surgery for benign conditions.
RNA isolation
Samples were immediately frozen in liquid nitrogen after
surgery and stored at −80°C. Total RNA was extracted
using TRIzol (Invitrogen) according to the manufac-
turer’s instructions. Samples were enriched for small
RNAs up to 200 bp by size selection using Pure Link
miRNA Isolation Kit (LifeTech). RNA purity, integrity
and size distribution were assessed using an Agilent
2100 Bioanalyzer (Agilent Technologies).
Small RNA library generation and sequencing
Enriched RNA samples were processed using the Small
RNA Expression Kit according to the manufacturer’s
protocol (Small RNA expression kit, rev. C, Applied Bio-
systems). Briefly, RNA was first hybridized and ligated
with the adapter mix “A”, subsequently reverse tran-
scribed and treated with RNAse H. The obtained cDNA
libraries were PCR amplified, purified and size-selected
by PAGE, resulting in libraries containing inserted small
RNA sequences of 20–40 bp length. Size, integrity and
purity of the libraries were verified by the Agilent 2100Bioanalyzer (Agilent Technologies). cDNA libraries were
barcoded using the Solid RNA barcoding kit and ampli-
fied onto beads using emulsion PCR. Templated beads
were deposited on slides and analysed using the Applied
Biosystems SOLiD 4 Sequencer.Statistical and bioinformatics analyses
The quality filtered reads were mapped against all anno-
tated human mature miRNA sequences (miRBase v19.0)
[30] using the Lifetech Lifescope 2.5.1 Small RNA pipe-
line, filtering for rRNA, primers, and small non-miRNA
non-coding transcribed sequences such as tRNAs and
snoRNAs. Sequence counts were extracted and reformatted
with perl scripts from the pipeline output. Differential
expression analysis was performed with the edgeR Biocon-
ductor statistical library [31] version 3.0.8 on R version
2.15.3. TMM-normalized sequence counts in the libraries
were transformed in Counts Per Millions (CPM) according
to the formula: CPM= (normalized counts/total miRNA
matches) *1,000,000. After having estimated the tagwise
dispersion, genewise exact test [32] as implemented in
edgeR was used to measure the significance of differential
expression, using the gene “Pseudo-counts”. Sequences
were deemed significantly differentially expressed if (1) the
p-value given by this method was < 0.05, (2) the total count
was greater than 50 CPM in at least one group of samples,
and (3) there was at least a two-fold change in normalised
sequence counts between the two groups.
The validated target prediction of a panel of regu-
lated microRNAs was performed by interrogating the
‘Validated Target’ option of the miRWalk web soft-
ware [33]. Target genes of the miR-378 family were
predicted using TargetScan Human 6.2 (http://www.
targetscan.org/), miRanda (http://www.microrna.org/
microrna/home.do) and DIANA-microT version 3.0
(http://diana.cslab.ece.ntua.gr/microT/) algorithms. Anno-
tation and enrichment of functional pathways associated
with the miR-378 target genes were evaluated using the
Reactome database and associated analytical tools (http://
www.reactome.org/). The same miR-378 target gene list
was used as the starting dataset for the generation of a
Functional Interaction network analysis and related Gene
Ontology enrichment analysis as described [34,35]. Pre-
liminary isoMIR analysis was performed by selecting
from the YM500 miR-Seq database (http://ngs.ym.edu.tw/
ym500v2/index.php) the hsa-miR378a-3p isoforms which
had been found with at least 50.000 sequence reads in 40
different experiments, allowing 3 nt 5′ extensions, 3′ ex-
tensions and one mismatch with respect to the reference
miRBase mature sequence. The resulting 14 isomirs were
identified and counted in all the NSM, ARMS and ERMS
sequences using the bowtie 0.12.8 database search soft-
ware and ad-hoc created perl scripts.
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3p promoter region was performed using the program
CpG plot of the EMBOSS sequence analysis suite
(http://emboss.sourceforge.net/), with standard parame-
ters, and other softwares such as CpG island searcher
(http://cpgislands.usc.edu/) on the genome region chr5:
149107388–149112388 corresponding to the putative
has-miR378a-3p putative promoter.
Each experiment was repeated three times independ-
ently. All results were expressed as means ± standard
deviation (SD), and a p-value < 0.05 was used for signifi-
cance. One-way ANOVA analysis for independent sam-
ples was used to determine statistical significance in
different assays.
Cell cultures
Human ARMS RH30 and ERMS RD cell lines were
maintained in high-glucose Dulbecco’s modified Eagle’s
medium(DMEM-HG) supplemented with 10% foetal
bovine serum (FBS), 1% v/v L-glutamine, 100 μg/ml
streptomycin and 100 U/ml penicillin, and grown at 37°C
in a humidified atmosphere of 5% CO2.
5-aza-2′-deoxycytidine treatment
RH30 and RD cells were seeded at 4 × 105 cells/well in
6-well plates. After 24 h, 5-aza-dC (Sigma-Aldrich, St.
Louis, MO) was added to a final concentration of
20 μM. Following different times of treatment, cells were
collected for cell cycle analysis, apoptosis, MTT, migra-
tion, Q-PCR, western blot or immunofluorescence.
Mock treatments were carried out treating cells in the
same medium with DMSO (Ctr).
Transient transfection
RH30 and RD cells were seeded at 8 × 105 cells/well in
6-well plates; miRNA mimics (miR-378a-3p, Dharmacon
Research) or negative control (miR-Ctr, Dharmacon
Research) were transfected using Lipofectamine 2000 re-
agent (Life Technologies) at 50 nM final concentration,
following the manufacturer’s protocol. Following differ-
ent times of treatment, cells were collected for cell cycle
analysis, apoptosis, MTT, migration, Q-PCR, western
blot or immunofluorescence.
Quantitative Real Time PCR (Q-PCR)
Reverse transcription (RT) for human miR-378a-3p,
miR-378a-5p, miR-483-3p and miR-503-5p was carried
out with TaqMan MicroRNA Assay kit (Life Technolo-
gies) using 20 ng of total RNA sample and the specific
stem-loop primer according to manufacturer’s protocols.
Quantitative Real Time PCR (Q-PCR) analysis was
performed on a StepOne Real Time System (Life Tech-
nologies) machine using miRNA-specific TaqMan MGB
primers/probe (Life Technologies). PCR reactions wererun at 95°C for 10 min, followed by 40 cycles at 95°C for
15 s and 60°C for 30 s. Data were normalized to U6
small nuclear RNA (RNU6) levels. Each sample was run
in triplicate. The amount of each miRNA was calculated
by the comparative Ct method and expressed as fold
change (2-ΔΔCT) compared to NSM using the DataAssist
v3.01 software (Life Technologies).
MTT assay
RH30 cells were treated with 5-aza-dC or transfected
with miRNA mimics, and cell viability was determined
using MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltet-
razolium] assay. Cells (5×103) were plated onto 96-well
plates in sextuplicates and, after 24 h, treated with
5-aza-dC or transfected with synthetic miR-378-3p; un-
treated and blank cell-free controls were included. At
designated times after treatment or transfection (0-24-
48-72 h), 10 μl of MTT (5 mg/mL, Sigma-Aldrich) were
added to each well and plates were incubated at 37°C for
4 h. Media were removed and 150 μl dimethyl sulfoxide
(DMSO) were added into each well to dissolve the dark
blue formazan crystals. Absorbance was measured at
wavelength of 550 nm, with reference at 630 nm, using a
microtitre plate reader (Select Science). The results were
plotted as means ± SD of two separate experiments hav-
ing six determinations per experiment for each experi-
mental condition.
Cell cycle analysis
RH30 and RD cells treated with 5-aza-dC were collected
and washed twice with phosphate buffered saline (PBS).
After fixation in 70% ice-cold ethanol overnight at +4°C,
cell pellets were washed twice with ice-cold PBS and
treated with RNase A for 15 min at 37°C. Propidium
iodide (PI) was added to each sample and DNA content
was determined by collecting 10,000 events using a BD
FACS Calibur Flow Cytometer (BD Biosciences). Data
were analysed using CellQuest Pro software (BD Biosci-
ences). Experiments were performed three times.
Apoptosis analysis
Cell apoptosis was analysed by flow cytometry with PE
Annexin V Apoptosis Detection Kit I (BD Pharmingen).
Briefly, RH30 and RD cells were seeded overnight in 6-
well plate and treated with 5-aza-dC or transfected with
miRNA mimics for 72 h. Cells were washed twice in
cold PBS and resuspended in 1x Annexin V Binding
Buffer at a concentration of 1×106 cells/ml. Cells were
stained with Annexin V and 7-Amino-Actinomycin D
(7-AAD) for 15 min at room temperature (RT) in
darkness according to the manufacturer’s instructions.
Annexin V and 7-AAD fluorescence intensities of con-
trol or treated samples were analysed using a BD FACS-
Calibur Flow Cytometer (BD Biosciences). Data were
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Experiments were performed three times.
Migration assay
RH30 cells were cultured in complete medium with 5-
aza-dC or miRNA mimics for 72 h before plating 5×104
cells per well into BD FalconTM Cell Culture Inserts
with 8 μm pore polycarbonate filters (Falcon). Chambers
with cells contained medium without serum, whilst the
lower well had DMEM supplemented with 10% FBS,
used as chemoattractant. After 24 h, migrated cells at
the base of the inserts were fixed in 100% methanol and
stained with 2% crystal violet dye. Cells were photo-
graphed under a light microscope at 20× or 40× magnifi-
cations; 8 randomly selected fields were examined and
counted manually. The average number of migrated cells
was calculated. Experiments were performed in triplicate
and repeated twice.
Western blot analysis
RMS cells were seeded overnight in 6-well plates. Cells
were treated with 5-aza-dC or transfected with miRNA
mimics for 72–96 h and lysed with Hepes buffer
(20 mM Hepes, 250 mM NaCl, 0.1% Triton X-100,
2 mM EDTA, 10 μg/mL leupeptin, 10 μg/mL aprotinin,
0.5 mM phenylmethylsulfonyl fluoride, 4 mM sodium
orthovanadate, 1 mM DTT). Total protein extracts (30 μg)
were separated on 8-12% sodium dodecyl sulfate (SDS)-
polyacrylamide gel (PAGE) and transferred onto polyvinyli-
dene fluoride (PVDF) membranes (Millipore Corporation,
Bedford, MA). Filters were blocked with 5% non-fat dry
milk in PBS-Tween for 30 min at RT and incubated with
the primary antibody. The following antibodies were incu-
bated over-night at +4°C: anti-IGFR1 (Cell Signaling),
anti-phospho-Akt (Cell Signaling), anti-MyoR(Santa Cruz
Biotechnology), anti-MyOD1 (Millipore), anti-Myf5 (Milli-
pore), anti-desmin (Millipore) and anti-MyHC (Millipore).
Appropriate horseradish peroxidase (HRP)-conjugated sec-
ondary antibodies (Santa Cruz Biotechnology) were used
for 1 h at RT. Protein-antibody complexes were detected
with ECL Super Signal (Pierce). Tubulin (Sigma-Aldrich)
was used as a normalization control for equal loading. Ex-
periments were performed at least three times.
Immunofluorescence
RMS cells were seeded overnight in 24-well plates. Cells
were treated with 5-aza-dC or transfected with miRNA
mimics for 72 h and then seeded into 8-chamber culture
slides (Falcon). After two additional days, cells were
rinsed with PBS and fixed with 4% paraformaldehyde at
RT for 30 min. After treatment with 0.1 M glycine and
permeabilisation with 0.1% Triton X-100, cells were sub-
jected to immunofluorescence staining with the anti-
MyHC (Millipore) antibody for 1 h 30 min at RT. Cellswere washed with cold PBS three times and incubated
with Texas Red-anti-mouse secondary antibody (1:100,
Jackson Laboratories) at RT for 30 min. The actin cyto-
skeleton was visualized with TRITC-phalloidin (1:50,
Sigma) at RT for 1 h 30 min. Nuclei were counter-
stained with 1 μg/ml Hoechst (Sigma). Labelled sections
were examined and analysed by using a Zeiss ApoTom
epifluorescent microscope (Carl Zeiss) and Axio-Vision
software. Experiments were replicated twice.
DNA Methylation analysis
Genomic DNA from RH30 cells treated or not with 5-aza-
dC for 72 h was obtained by phenol:chloroform:isoamyl
alcohol method. About 1 μg of DNA was modified using
the Epitect DNA Bisulfite Kit (Qiagen), according to the
manufacturer’s protocol. For sequencing, the bisulfite-
treated DNA was amplified by PCR with two different pri-
mer sets for the human miR-378a promoter: BS1 forward
5′-GGGGAAAAGttAGGtTGGA-3′ and BS1 reverse
5′-aCTaACATTTTTaaTaaCTaCTTaTCCCAaC-3′; BS2
forward 5′-GGGTAAtTGGGGGTTttAG-3′ and BS2 re-
verse 5′-CAaCAACAaCACTCTaaaaACT-3′. PCR prod-
ucts, purified using a commercially available kit (Qiagen),
were sequenced on an ABI sequencer with dye terminators
(Applied Biosystems). Analysis of primary bisulfite sequen-
cing was carried out with BISMA software (http://services.
ibc.uni-stuttgart.de/BDPC/BISMA) by uploading the un-
converted reference sequence and the sequencing results.
For methylation-specific PCR (MSP), the bisulfite-modified
genomic DNA was amplified using primers based on
methylated (M) or unmethylated (UM) cytosines in
CpG islands in the miR-378a promoter region: M
forward 5′-AGtTAGCGGtttTGCGGtAGtC-3′ and M
reverse 5′-aCCCGaaaaaAaaaAaCCAaCGAaCG-3′; UM
forward 5′-tttGtttttGtAGtTAGtGGtttTGtGGtAGttG-3′
and UM reverse 5′-CaAaCCaaCCCaaaaaaAaaaAaCCAa
CaAaCa-3′. PCR products were run on 2% agarose gel.
All primers were designed using the MSPprimer algo-
rithm. Experiments were performed three times.
Results
Small RNA library generation, sequencing, identification
and quantification of annotated miRNAs
As accumulating evidence indicates that miRNAs play
important roles in cancer development, including RMS,
this study profiled the miRNA transcriptome by the dir-
ect sequencing of mature miRNA molecules in a panel
of primary RMS tumours. RNA was prepared from four
ARMSs and four ERMSs, and from a pool of NSM ob-
tained from eight donors. As RMS has a mainly infiltra-
tive growth pattern, the quantity of available tumour
samples is very often a limiting factor, especially for
controls and NGS experiments. Hence, we used a set of
pre-pooled NSM samples from already available normal
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some loss in biological variability. However, relevant
differential representation of single miRNA molecules
stood out clearly in a comparison of individual samples
versus a pooled control, minimizing the inter-individual
‘transcriptional noise’. Clinical characteristics of the
tumour cases are reported in Table 1. Small RNA librar-
ies were prepared and deep sequenced by using a
SOLiD4 Sequencer platform. The corresponding nine
cDNA libraries yielded a total of 250 million sequenced
reads, and more than 85% of these reads (an average of
22 million per library) mapped against the human refer-
ence genome (GRCh37/hg19, repeat masked). The reads
corresponding to annotated miRNAs were identified by
selecting all reads mapping against the human precursor
and mature sequences comprised in miRBase v19.0.
After passing alignment quality filtering, from 2 to 7
million reads were identified as annotated miRNAs per
library (on average 15% of hg19 mapped reads), repre-
senting 685 different mature miRNA molecules. The
abundance value of each target-miRNA was normalized
using TMM normalization, scaled to “counts per mil-
lion” (CPM) in respect to each library size and the asso-
ciated “pseudo-counts” were used for the differential
expression analysis. Figure 1 and Table 2 show the distri-
bution of the different miRNA species in abundance
classes comparing ARMS and ERMS samples against
NSM, allowing a survey of the whole miRNA popula-
tion. Apparently, tumour miRNAs on average were more
represented in the intermediate abundance class (102-
104 CPM), whilst they were under-represented in the
lowest (1-102 CPM) and in the highest abundance (>104
CPM) classes. These data support the hypothesis that in
these tumours a rearrangement of miRNA expression
levels occurred, resulting in a reduction of the levels ofFigure 1 miRNAs in alveolar and embryonal RMS (ARMS and ERMS) s
the number of different miRNA species in function of transcript expression
Distribution of transcripts in abundance classes (Low < 1-102 CPM; Intermesome highly expressed miRNAs and a simultaneous
slight increase of the expression of many low-abundance
miRNA species.
The distribution of miR-387a-3p isomirs between NSM
and RMSs was assessed. One YM500 database isoform
with an extension at 3′ and a mismatch in the extension
(ACTGGACTTGGAGTCAGAAGGCG[C]T) was repre-
sented in both NSM and ARMS/ERMS samples, but with
a noticeable difference in frequency which will warrant
further investigation.
Differentially expressed miRNAs
Of a total of 685 expressed miRNAs, 97 (14.2%) dis-
played significant differential levels collectively in ARMS
and ERMS tumours in comparison with NSM. Notably,
out of these 97, 79 (81.4%) miRNAs were expressed at
lower levels in RMSs using the TMM normalization
(Table 3A), whilst 18 (18.6%) were expressed at higher
levels (Table 3B). Of note, using a different edgeR
normalization method (upper quartile) only produced 4
additional differentially expressed miRNAs, while main-
taining the total number of detected small RNAs.
Among the identified differentially expressed miRNAs,
some have been previously associated with tumour devel-
opment in RMS [36]. Interestingly, miRNAs belonging to
the miR-378 family, recently suggested to be essential in
normal skeletal muscle development [37], were markedly
down-regulated in both ARMS and ERMS tumours (see
Additional file 1: Table S1). MiR-133a, miR-378a-3p, miR-
378a-5p, miR-483-3p and miR-503-5p were selected as
candidates to validate miRNA expression levels in Q-PCR
using the eight deep-sequencing-analysed RMSs, seven
additional tumour samples (3 ARMSs and 4 ERMSs) along
with four different RMS cell lines (RH4 and RH30 ARMS
cell lines; and RD and RD18 ERMS cell lines). Inamples, together with normal skeletal muscle (NSM). Graphic of
levels, expressed in Log2CPM, in ARMS, ERMS and NSM samples.
diate 102-104 CPM; High > 104 CPM) is schematized.
Table 2 Distribution in abundance classes of different miRNA transcripts in tumours and normal muscle
NMS RHABDOMYOSARCOMAS
CLASSES CPM range miRNA species Cumulative CPM % CPM miRNA species Cumulative CPM % CPM
LOW ABUNDANCE 1 - 102 498 9,663 1.0 369 9,288 0.9
INTERMEDIATE ABUNDANCE 102 - 104 163 214,726 21.5 296 451,671 45.2
HIGH ABUNDANCE >104 16 775,611 77.5 20 539,041 53.9
TOTAL 677 1,000,000 100.0 685 1,000,000 100.0
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results confirmed the down-regulation of miR-133a, miR-
378a-3p and miR-378a-5p, as well as the over-expression of
miR-483-3p and miR-503-5p in the RMS tumour tissues
(see Additional file 2: Figure S1A) and cells (see Additional
file 2: Figure S1B). Comparison of deep sequencing ARMS
and ERMS data showed a similar range of gene expression
profile with the exception of a limited number of miRNAs
that displayed significantly different levels (Table 3C).
miR-378a-3p negatively regulates IGF1R levels
As reported in Table 4, miR-378 family members are
transcribed from different loci but they exhibit seed se-
quence homology for mRNA target recognition. We fo-
cused on miR-378a-3p, a key regulatory molecule of
miR-378 family, investigating the biological relevance of
this miRNA in RMS tumours by performing target gene
prediction and functional pathway analysis. TargetScan,
DIANA-microT, miRanda and miRWalk algorithms
were interrogated, which allowed the identification of a
list of putative/validated mRNA targets for miR-378a-3p
(see Additional file 3: Table S2). DAVID and Cytoscape
Reactome FI, used to functionally cluster the miRNA
targeted transcripts and their involvement in various sig-
nal pathways, showed a significant enrichment in bio-
logical mechanisms and pathways linked with neoplastic
diseases and, more specifically, with apoptosis, cell cycle
signalling and DNA remodelling/interaction (see Additional
file 3: Table S2). Interestingly, the in silico analysis
suggested that miR-378a-3p directly participates in the
post-transcriptional regulation of IGF1R signalling
(Figure 2A), which is involved in the development,
growth, proliferation, cell survival and metastasis
of RMS [38]. To validate the control of the IGF1R
expression, transient transfection ofmiR-378a-3p in
RH30 cells, an in vitro model of human ARMS, was
carried out. An RNA duplex from C. elegans was used
as a negative miRNA-Control (miR-Ctr). Using by
stem-loop real-time PCR, specific expression increase
of miR-378a-3p after transfection with the respective
mimic was demonstrated (see Additional file 4: Figure
S2). A down-regulation of the endogenous IGF1R pro-
tein levels was observed in miR-378a-3p-transfected
RH30 cells (Figure 2B) consistent with the conserved
binding sites for this miRNA in the 3′-untranslatedregion of IGF1R transcript (Figure 2C), identified by
computational tools for miRNA target prediction.
IGF1R reduction was also confirmed in RD cells transi-
ently transfected with miR-378a-3p (data not shown).
These data are also in agreement with those reported by
other research groups [39-41] in which the direct regula-
tion of IGF1R mRNA by miR-378a-3p was supported by
in vitro luciferase assays. Thus, expression of miR-378a-3p
suppresses IGFR1 pathway activity.
miR-378-3p induces apoptosis and impairs cell migration
In order to examine the potential anti-oncogenic role
of miR-378a-3p in RMS, a series of in vitro gain-of-
function experiments were designed. A significant in-
crease of apoptotic cells was observed in alveolar RH30
at 72 h following transfection of miR-378a-3p mimics
(30.8% ± 1.0) in comparison with miR-Ctr (16.3% ± 2.4)
(Figure 3A). Similarly, the number of apoptotic cells sig-
nificantly increased in miR-378a-3p transfected embry-
onal RD cells versus miR-Ctr positive cells (24.1% ± 2.9
vs. 11.2% ± 1.9, p < 0.01). Consistent with the FACS re-
sults, a decrease of AKT phosphorylation levels and a
concomitant increase of cleaved-caspase-3, an important
regulator of apoptosis, were detected in miR-378a-3p
positive cells compared to scrambled control-treated
RH30 cells (Figure 3B). Only a moderate alteration
(about 20%) in cellular viability/proliferation rate was
evident in miR-378a-3p-transfected RH30 cultures
(Figure 3C). Ectopic expression of miR-378a-3p signifi-
cantly suppressed by about 60% the ability of RH30 cells
to migrate through Boyden chamber membranes to-
wards serum-containing medium when compared with a
mimic negative control (Figure 3D). These results indi-
cate that the restoration of miR-378a-3p levels enhances
programmed cell death and inhibits cell viability and mi-
gration potentials of RMS cells.
miR-378a-3p correlates with myogenic differentiation
Expression analysis was carried out using a panel of
muscle markers in RH30 cells transfected with miR-378a-
3p in order to assess whether miRNA up-regulation was
able to promote skeletal muscle differentiation. The modi-
fications found in specific myogenic marker levels were
consistent with the induction of myogenic differenti-
ation both in immunoblotting and immunofluorescence
Table 3 miRNA expression in RMS tumours
A B
miRNA_ID log2FC log2CPM miRNA_ID log2FC log2CPM miRNA_ID log2FC log2CPM
hsa-miR-885-5p −6.93 7.34 hsa-miR-4256 −2.95 9.13 hsa-miR-4327 9.95 3.61
hsa-miR-144-5p −5.62 8.27 hsa-miR-218-5p −2.95 11.07 hsa-miR-508-3p 9.63 3.40
hsa-miR-451a −5.52 15.36 hsa-miR-126-3p −2.93 13.30 hsa-miR-383 7.99 6.17
hsa-miR-1 −5.47 16.81 hsa-miR-5787 −2.93 3.93 hsa-miR-503-5p 5.68 9.48
hsa-miR-378a-5p −5.34 11.64 hsa-miR-22-5p −2.88 9.77 hsa-miR-154-3p 5.19 10.09
hsa-miR-223-3p −5.12 12.89 hsa-miR-30e-3p −2.81 9.06 hsa-miR-493-5p 4.89 11.33
hsa-miR-124-3p −5.06 5.79 hsa-miR-139-5p −2.79 9.02 hsa-miR-450a-5p 4.88 9.11
hsa-miR-378a-3p −4.92 13.79 hsa-miR-30b-3p −2.77 3.39 hsa-miR-500b 4.68 9.25
hsa-miR-378f −4.80 7.02 hsa-miR-203a −2.72 5.26 hsa-miR-335-3p 4.60 9.51
hsa-miR-378 h −4.53 4.42 hsa-miR-185-5p −2.71 8.80 hsa-miR-376c-5p 4.59 4.14
hsa-miR-378c −4.47 12.37 hsa-miR-652-3p −2.68 7.09 hsa-miR-483-3p 4.55 13.10
hsa-miR-599 −4.39 4.93 hsa-miR-4484 −2.64 3.45 hsa-miR-376a-2-5p 4.55 5.55
hsa-miR-144-3p −4.36 7.41 hsa-miR-208b −2.63 5.74 hsa-miR-503-3p 4.55 4.22
hsa-miR-378i −4.29 6.47 hsa-miR-24-1-5p −2.60 5.69 hsa-miR-3182 4.43 7.92
hsa-miR-378d −4.29 8.81 hsa-miR-30a-3p −2.60 8.81 hsa-miR-542-3p 4.36 10.77
hsa-miR-486-5p −4.14 11.78 hsa-miR-29a-3p −2.59 13.25 hsa-miR-149-5p 4.33 11.39
hsa-miR-133a −4.05 14.25 hsa-miR-16-2-3p −2.55 8.81 hsa-miR-501-5p 3.81 11.03
hsa-miR-95 −3.96 9.35 hsa-miR-628-3p −2.54 2.47 hsa-miR-483-5p 3.48 9.68
hsa-miR-378b −3.86 5.55 hsa-miR-29b-2-5p −2.54 5.75
hsa-miR-29c-5p −3.82 7.35 hsa-miR-133b −2.53 11.85 C
hsa-miR-378e −3.82 9.31 hsa-miR-4300 −2.51 4.76 miRNA_ID log2FC log2CPM
hsa-miR-142-5p −3.68 8.68 hsa-miR-491-5p −2.32 2.56 hsa-miR-335-5p −3.25 12.19
hsa-miR-4461 −3.66 2.84 hsa-miR-873-3p −2.31 3.06 hsa-miR-489 −3.30 7.64
hsa-miR-378 g −3.64 4.58 hsa-miR-3687 −2.31 2.75 hsa-miR-375 −4.11 8.33
hsa-miR-944 −3.56 2.73 hsa-miR-5095 −2.27 4.86 hsa-miR-135a-5p −5.38 10.49
hsa-miR-486-3p −3.54 6.75 hsa-miR-29b-1-5p −2.26 3.58 hsa-miR-9-3p −6.07 6.89
hsa-miR-29c-3p −3.54 12.27 hsa-miR-664a-5p −2.25 3.52 hsa-miR-9-5p −7.53 8.95
hsa-miR-4306 −3.53 3.61 hsa-miR-664a-3p −2.24 7.74 hsa-miR-499a-3p 6.21 7.83
hsa-miR-4516 −3.51 3.57 hsa-miR-4315 −2.22 4.39 hsa-miR-499a-5p 6.07 9.97
hsa-miR-193b-5p −3.51 6.08 hsa-miR-3714 −2.21 2.64 hsa-miR-432-5p 3.58 9.47
hsa-miR-139-3p −3.49 2.94 hsa-miR-4787-3p −2.18 2.50 hsa-miR-296-5p 3.37 8.53
hsa-miR-616-5p −3.41 4.29 hsa-miR-7-5p −2.14 6.83 hsa-miR-95 3.30 7.89
hsa-miR-22-3p −3.39 9.05 hsa-miR-7-1-3p −2.13 7.81 hsa-miR-31-5p 3.22 8.09
hsa-miR-150-5p −3.33 10.54 hsa-miR-7-2-3p −2.06 3.97
hsa-miR-548v −3.27 3.04 hsa-miR-23c −1.98 9.82
hsa-miR-3117-3p −3.05 1.97 hsa-miR-584-5p −1.96 2.87
hsa-miR-628-5p −3.03 5.41 hsa-miR-137 −1.95 5.54
hsa-miR-1281 −3.02 3.73 hsa-miR-3607-5p −1.64 10.85
hsa-miR-548z −3.01 3.45 hsa-miR-935 −1.59 5.49
hsa-miR-126-5p −3.00 12.54
(A) miRNA species expressed at lower levels in RMSs vs. NSM (ARMS and ERMS are collectively considered); (B) miRNA species expressed at higher levels in RMSs
vs. NSM (ARMS and ERMS are collectively considered); (C) differentially expressed miRNAs in ERMS vs. ARMS tumours.
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Table 4 Human miR-378 family members
miRNA_ID Accession Sequence Locus (strand) Start End
hsa-miR-378a-3p MIMAT0000732 ACUGGACUUGGAGUCAGAAGG Chr5 (+) 149112388 149112453
hsa-miR-378b MIMAT0014999 ACUGGACUUGGAGGCAGAA Chr3 (+) 10371913 10371969
hsa-miR-378c MIMAT0016847 ACUGGACUUGGAGUCAGAAGAGUGG Chr10 (−) 132760851 132760931
hsa-mir-378d-1 MIMAT0018926 ACUGGACUUGGAGUCAGAAA Chr4 (−) 5925002 5925055
hsa-mir-378d-2 MIMAT0018926 ACUGGACUUGGAGUCAGAAA Chr8 (−) 94928250 94928347
hsa-miR-378e MIMAT0018927 ACUGGACUUGGAGUCAGGA Chr5 (+) 169455492 169455570
hsa-miR-378f MIMAT0018932 ACUGGACUUGGAGCCAGAAG Chr1 (+) 24255560 24255637
hsa-miR-378 g MIMAT0018937 ACUGGGCUUGGAGUCAGAAG Chr1 (−) 95211416 95211456
hsa-miR-378 h MIMAT0018984 ACUGGACUUGGUGUCAGAUGG Chr5 (+) 154209018 154209100
hsa-miR-378i MIMAT0019074 ACUGGACUAGGAGUCAGAAGG Chr22 (−) 42319226 42319301
hsa-miR-378j MIMAT0024612 ACUGGAUUUGGAGCCAGAA Chr17 (−) 35974976 35975084
hsa-miR-378a-5p MIMAT0000731 CUCCUGACUCCAGGUCCUGUGU Chr5 (+) 149112388 149112453
MiRBase (Release 21, June 2014) identifiers, accession numbers, sequence and genome location of human miR-378 family members. The presence of a shared
common seed is evident from the aligned sequences.
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http://www.biomedcentral.com/1471-2407/14/880experiments, performed 96–120 h after miR-378a-3p
induction (Figure 4). In particular, RH30 cells trans-
fected with miR-378a-3p mimics showed a slight up-
regulation of MyoD1 and MyHC proteins, which are
respectively detected in committed proliferating myoblasts
and in post-mitotic muscle cells, with a concomitant
down-regulation of MyoR, a repressor of myogenesis, and
Myf5, an helix-loop-helix transcription factor correlated
with myoblast proliferation stage (Figure 4A). Myoid differ-
entiation was also confirmed by the up-regulation of the
intermediate filament desmin, the contractile protein actin
expressed in skeletal muscle cells (Figure 4A). Furthermore,
an increased number of miR-378a-3p transfected cells ex-
hibited changes in morphology/cytoskeleton organization
and moderate levels of MyHC staining (Figure 4B). In par-
ticular, more organized actin filaments were observed in
miR-378a-3p positive cells, whilst actin appeared more
diffusely distributed through-out the cytoplasm in
mocked RH30 control cells, as documented by TRITC-
phalloidin staining (Figure 4B). MyHC immunofluores-
cence staining had stronger intensity also in RD cells
transfected with miR-378a-3p than miR-Ctr (data not
shown). These experiments suggest that miR-378a-3p
molecules are involved in the reactivation of terminal
myogenic differentiation in RMS by coordinating spe-
cific regulatory factors and repressors.
5-aza-2′-deoxycytidine (5-aza-dC) treatment up-regulates
miR-378a-3p levels and induces apoptosis, G2-cell arrest
and decreased migration in RMS cells
Since epigenetic modifications have been involved in
miRNA deregulation, treatment of RH30 and RD cells
with 5-aza-dC, a demethylating drug, was carried out to
see if it could have a direct effect on miR-378a-3p levels
given the presence of CpG islands in its promoter region(Figure 5A). Incremental dosing of 5-aza-dC (2-10-
20 μM) resulted in up-regulation of the abundance of
mature miR-378a-3p molecules compared with the con-
trol after 24 h (Figure 5B). A similar miR-378a-3p incre-
ment (about 3.5 fold-change) was observed in RD
treated-cells (data not shown). In this investigation, we
analysed the miR-378a-3p methylation pattern in RH30
cells, either untreated or treated with 5-aza-dC for 72 h.
DNA was subjected to bisulfite sequencing (BS) and
methylation-specific PCR (MS-PCR). Surprisingly, we
had no evidence of methylated CpG islands either in Ctr
(upper line) than in 5-aza-dC-treated cells (lower line)
by sequencing BS1 and BS2 miR-378a-3p promoter re-
gions (Figure 5C). Unmethylated pattern was also sug-
gested by PCR positivity using primer sets specific for
the miR-378a-3p unmethylated CpG (UM) but not with
methylated CpG (M) specific primers (Figure 5D). The
addition of 20 μM 5-aza-dC was able to efficiently trig-
ger apoptosis in alveolar RH30 cells (36.7% ± 3.6 vs.
12.4% ± 2.2) (Figure 6A), whilst the amount of apoptotic
cells was less in 5-aza-dC embryonal RD cells versus
mocked control cells (26.1% ± 3.8 vs. 12.1% ± 2.0, p <
0.05). The migration capacity of the 5-aza-dC-treated
RH30 cells was significantly diminished compared with a
paired negative control (Figure 6B). Furthermore, a
significant growth/cell cycle arrest of RH30 cells was
evident after drug exposure. The addition of the
demethylating drug resulted in the appearance of a small
number of living cells with a different morphology com-
pared to untreated control cells. A time-dependent in-
hibition of cell proliferation resulted in a peak of 80% at
72 h post-treatment in RH30 cells (Figure 6C). Similarly,
5-aza-dC reduced migration and proliferation rates of
RD cells of about 50% (data not shown). To determine
whether growth inhibition was associated with specific
Figure 2 miR-378a-3p negatively regulates IGF1R. (A) Schematic network representation of miR-378a-3p target genes functional annotations
and interactions obtained from Cytoscape Reactome FI interrogation. IGF1R represents the principal mRNA target of miR-378a-3p. Putative mRNA
targets of miR-378a-3p are predicted to be involved in several signal pathways, specifically apoptosis, cell cycle and chromatin remodelling. Arrow
(edge) orientation indicates positive, negative or undetermined functional interaction between different genes (network nodes). Target gene
colours indicate different functional modules of the interaction network. (B) Immunoblot analysis. Validation of miR-378a-3p direct participation
in the post-transcriptional regulation of IGF1R in RH30 cells (miR-control vs. miR-378a-3p positive cells). Tubulin was used as loading control.
(C) Sequence alignment of miR-378a-3p seed sequence (highlighted) with IGF1R 3′-UTR binding sites (bold letters in the yellow box; position
5589–5596 of human IGF1R: NM_000875) in different species. Data from TargetScan Human 6.2 interrogation.
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cells after 72 h of 5-aza-dC exposure. Cell cycle distribu-
tion analysis in RH30 cells showed a significant accumu-
lation of cells in the G2 phase in 5-aza-dC treated cells
compared with controls (51.% ±2.1 vs. 19.9% ±3.1, p <
0.001), while the percentage of cells in the G1 phase de-
creased by 50% (28.4% ±5.1 vs. 60.5% ±3.2, p < 0.01)
(Figure 6D). Analogous trend was observed in RD cells
treated with 5-aza-dC compared with mocked control
(G2 phase: 50.2% ±1.1 vs. 35.9% ±1.7, p < 0.01; G1
phase: 30.1% ±0.9 vs. 47.5% ±1.3, p < 0.01).
These results indicate that demethylation inhibits via-
bility and proliferation of RMS cells due to G2 cell cycle
arrest and programmed cell death, and that it might also
affect RMS progression by reducing cell migration.5-aza-dC treatment induces myogenic differentiation
Finally, to assess whether 5-aza-dC treatment can also
promote myogenic differentiation in RMS, RH30 cells
were exposed to the demethylating drug followed by as-
sessment of myogenic markers by immunofluorescence
experiments. RH30 cells treated with 5-aza-dC exhibited
marked changes in the cytoskeleton structure, as evident
by phalloidin staining, and a differentiated phenotype,
supported by the MyHC positivity (Figure 6E).
Taken together, these data are partially consistent with
those following miR-378a-3p transfection, although the
effects in RMS cells are more pronounced, this being
due to the fact that 5-aza-dC action is not limited to the
regulation of an individual miRNA but that it facilitates
the re-expression of several epigenetically silenced genes.
Figure 3 miR-378a-3p involvement in apoptosis, cell proliferation and migration of RMS cells. (A) FACS analysis. Increase of apoptotic
cells (Annexin V-positive) in miR-378a-3p compared to miR-Control positive RH30, 72 h after transfection. Results in the bar chart are the means ±
standard deviation (SD) of three separate experiments. (B) Immunoblot analysis, 72 h after transfection. Reduction of phosho-AKT (pAKT) levels
and up-regulation of cleaved caspase-3 in RH30 positive cells in comparison to miR-Ctr transfected cells. Total AKT andcaspase-3 levels were
similar in both samples. Tubulin was used as loading control. (C) MTT assay. Alteration of the cell viability/proliferation rate in miR-378a-3p transfected
RH30 compared with mock control cells. Results are means ± SD of sextuplicate points of two separate experiments. (D) Migration assay. miR-378a-3p
transfected RH30 cells compared to negative control cells showed decreased ability to migrate through Boyd chamber membranes. Representative
fields of migrated cells through the membrane, stained with crystal violet dye (20× magnification). Data was obtained from the average migration cell
number per field (n =8) ± SD of triplicate experiments performed twice. Asterisks denote data in which miR-378a-3p was significantly different from
control (*, p < 0.05; **, p < 0.01; ***, p < 0.001).
Megiorni et al. BMC Cancer 2014, 14:880 Page 11 of 17
http://www.biomedcentral.com/1471-2407/14/880Discussion
RMS is a malignant tumour occurring most commonly
in the paediatric population, with a survival of around
20% when metastatic disease is present at diagnosis [42].
MiRNAs seem to play a crucial role in RMS development
and progression, and might represent novel tools for im-
proving the outcome of this malignancy [12,43,44]. In this
study, the expression levels of miRNAs were measured in
a panel of alveolar and embryonal tumours by using deep
sequencing technology in order to identify key drivers of
RMS specific processes. The global miRNA abundance
was reduced in RMS, this contributing to the neoplastictransformation by allowing an increased expression of
proteins with oncogenic potential, as previously observed
[17]. Notably, many relevant myo-miRNAs, such as miR-
1, miR-133a and miR-29, were markedly down-regulated
in tumour samples in comparison to NSM, as already
shown in previous studies carried out by microarray or
Q-PCR technologies [21,37]. Interestingly, mir-206 was
present with a detectable negative fold change in all com-
parisons but without being associated with a significant
statistical index in the final analysis, as also reported in
recent published microarray experiments carried out in
the same biological model [45]. MiRNAs expression was
Figure 4 miR-378a-3p activates myogenic differentiation. (A) Immunoblot experiments. RH30 cells transfected with miR-378a-3p mimics or
miR-Ctr were analysed for the expression of myogenic differentiation markers. Increased levels of MyoD1 (1.6-foldchange by densitometry), desmin and
MyHC proteins and down-regulation of MyoR and Myf5 factors were evident. Tubulin served as protein loading control. (B) Immunofluorescence analysis.
MiR-378a-3p ectopic expression evoked noticeable changes in RH30 cell morphology, a more organized actin and myosin arrangement, as visualised by
TRITC-phalloidin staining, and a significant positivity for anti-MyHC antibody (100× magnification).
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a restricted number of small regulatory molecules seemed
to discriminate the two RMS subtypes. Further analyses
need to be undertaken to understand the possible differen-
tial role of specific miRNAs and related pathways in
ARMS and ERMS oncogenic transformation, and to deter-
mine the potential role of miRNAs as diagnostic bio-
markers in the two RMS subtypes.
To our knowledge, this is the first study that shows a
marked down-regulation of miR-378 family members in
RMS. This finding is probably due to the improved spe-
cificity and sensitivity of deep sequencing compared to
microarray and Q-PCR analyses, deep sequencing also
allowing identification of novel MiRNA isoforms. MiR-
378 molecules were strongly under-expressed both in
ARMS and ERMS tumours, this showing that the regula-
tion of these miRNAs does not differentiate among RMS
subtypes. Interesting preliminary results showed a sig-
nificant difference in the abundance of one specific miR-
378a-3p 3′ isoform between RMS and NSM. miR-378
molecules are encoded by different genes but they share
identical seed sequences for mRNA target recognition.
The most important regulatory small RNA of this family
is miR-378a-3p, whose expression is highly variable in
different cancers, reflecting the complexity and specifi-
city of the miRNA response [46-48]. In addition, some
studies suggest that miR-378a-5p, the opposite strand of
miR-378a-3p, also has a functional relevance [49,50].
Our data confirmed that miR-378a-3p was significantly
reduced not only in RMS tumours but also in humanRMS cell lines, this finding suggesting a role of miR-
378a-3p as a tumour suppressor. Among the main path-
ways identified as potential targets for miR-378a-3p in
our bioinformatics analysis, we chose to focus on
IGF1R/AKT signalling, which has a well-established role
in cellular growth and survival as well as in myogenic
differentiation [40,51,52]. Ectopic expression of miR-
378a-3p in RH30, an ARMS-derived cell line, markedly
reduced IGF1R protein levels and promoted apoptosis
via phospho-AKT inhibition and concomitant caspase-3
activation. Furthermore, miR-378a-3p-transfected cells
moderately reduced cell proliferation and markedly cell
migration. Accordingly, miR-378a-3p has been shown to
be involved in carcinogenesis and an anti-oncogenic
function has been suggested both in nasopharyngeal [53]
and gastric cancer [47] through the negative regulation
of VEGF expression, a protein promoting cell migration
and inhibiting apoptosis. In a study by Martins et al.
[54], RMS development seemed to involve increased
IGF1R expression, which in turn enhanced AKT and
Bcl-XL-mediated cell survival. The moderate effects on
apoptosis and cell growth we observed in RH30 cells
could be explained by the presence of the t(2;13)(q35;
q14) translocation, since PAX3/FOXO1 chimeric protein
is directly involved in the regulation of the IGF1R
expression.
In accordance with the observation that in RMS prolif-
eration and migration are inversely related to myogenic
differentiation [3,55], we found that miR-378a-3p mimic
transfection was also able to promote myogenesis, as
Figure 5 miR-378a-3p response to 5-aza-dC treatment. (A) Schematic representation of the miR-378a-3p promoter region generated by EMBOSS
software. Bioinformatic analysis showed the presence of a high percentage of GC nucleotides and an enriched zone of CpG islands. (B) Effect of
increasing doses of 5-aza-dC (2-10-20 μM) on mature miR-378-3p levels compared with control RH30 cells 24 h after treatment. Results are means ± SD
of three separate experiments (**, p < 0.01; ***p < 0.001). (C) BISMA diagrams showing the methylation level of CpG dinucleotides in the miR-378a
promoter in 5-aza-dC and mocked control cells, as revealed by bisulfite sequencing of BS1 and BS2 regions. Blue rectangles indicate non-methylated
CpGs. (D) Methylation analysis of miR-378a promoter region by PCR using primer set for methylated (M) or unmethylated (UM) sequences. The presence
of a visible UM product indicates that CpG dinucleotides are not methylated in both Ctr and 5-aza-dC-treated cells.
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markers and by the changes in the cell morphology,
from star-round to a more elongated appearance. In par-
ticular, normalization of miR-378a-3p expression re-
duced the levels of MyoR, a MyoD1 inhibitor, thus
contributing to reactivate myogenesis; this was reflected
by the MyHC levels, which is specifically related to com-
mitted muscle cells. Furthermore, miR-378a-3p trans-
fected RH30 cells showed a more concentrated assembly
of actin bundles, a characteristic of the intermediate
muscle differentiation stage [56]. In accordance with
these results, recent works have reported miR-378a-3p
as a new candidate in skeletal muscle development
[37,57]. In C2C12 murine proliferating myoblasts, up-
modulation of miR-378 has been proposed as allowing
the efficient myotube formation by repressing antago-
nists of differentiation, like MyoR [57]. Likewise, the ex-
pression pattern of miR-378 in porcine longissimus
muscles is closely related to myogenesis regulation,
mainly with fibre formation [37]. Re-activation of skel-
etal muscle development in RMS seems to be linked tothe IGF1R inhibition, as demonstrated by miR-1 and
miR-133a [51,58]. Indeed, the marked down-regulation
of miR-378a-3p, miR-1 and miR-133a, and the concomi-
tant up-regulation of IGF1R observed in RMS tumours
could explain why cancer cells are prohibited from
undergoing terminal differentiation despite their com-
mitment to a myogenic pathway.
This study also underlines the relationship between
aberrant epigenetic regulation of tumour suppressors,
including miRNAs, and cancer development. The pres-
ence of CpG sites in the promoter regions of the miR-
378 family members has recently been suggested and
partially experimentally demonstrated in other neo-
plasms [47,59-61]. In our in vitro RMS model, treatment
with 5-aza-2′-deoxycytidine, a demethylating agent, was
able to restore the expression of mature miR-378a-3p
in a dose-dependent manner but without direct effect
on DNA methylation status. Therefore, the hyper-
methylation of CpG islands at the miR-378a-3p pro-
moter region does not represent a causative mechanism
for the marked down-regulation of this miRNA in RMS.
Figure 6 5-aza-dC involvement in apoptosis, cell proliferation, migration and differentiation of RMS cells. (A) FACS analysis. Increased
number of apoptotic RH30 cells after treatment with 20 μM 5-aza-dC along with paired negative controls (DMSO treatment). Results are the
means ± SD of three separate experiments. (B) Migration assay. 5-aza-dC treated RH30 cells, compared with control, showed significantly impaired
ability to cross through Boyd chamber membranes. Representative fields of migrated cells through the membrane, stained with crystal violet dye
(20× magnification). (C) MTT assay. Time-dependent inhibition of cell proliferation after 5-aza-dC treatment resulted in 80% decrease at 72 h. Data
are shown as means ± SD of sextuplicate points of two separate experiments. (D) FACS analysis. Cell cycle distribution of 20 μM 5-aza-dC RH30
treated cells showed a marked arrest in G2-phase after 72 h. Results are means ± SD of three separate experiments. (E) Immunofluorescence
analysis. Five-aza-dC exposure led to marked changes of RH30 cell morphology, to more organised actin bundles (TRITC-phalloidin staining)
and to MyHC positivity (100× magnification). Asterisks denote data in which miR-378a-3p was significantly different from control (**, p < 0.01;
***, p < 0.001).
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http://www.biomedcentral.com/1471-2407/14/880Indeed, many CpG islands located at genes that have
a tissue-restricted expression pattern, can remain
methylation-free even when their associated genes
are silent. Inactive unmethylated CpG island pro-
moters show elevated levels of dimethylation at his-
tone H3 lysine 4 (H3K4), suggesting that this
chromatin mark may protect DNA from methylation
[62]. In line with this model, recruitment of H3K4
methylases by unmethylated CpGs has recently been
suggested [63]. Notwithstanding, our data imply that
epigenetic modifications may play an indirect role onmiR-378a expression by acting on specific transcrip-
tion factors able to bind the miR-378a promoter re-
gion, which also warrant further study. Consistent
with the up-regulation of miR-378a-3p levels, 5-aza-dC
exposure affected apoptosis, proliferation and migration of
RMS cells, with more dramatic effects. In particular, the
resulting DNA hypomethylation arrested the cell cycle at
G2-phase with a concomitant induction of myogenic dif-
ferentiation, as demonstrated by the more elongated cell
morphology and enhanced MyHC expression. Most likely,
the fact that azacytidine has a much broader effect on the
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http://www.biomedcentral.com/1471-2407/14/880RH30 cellular phenotype reflects the fact that the tran-
scriptional activation is not limited to miR-378a-3p but in-
volves several epigenetically silenced genes. Aberrant
DNA methylation and histone deacetylation was reported
to have a key role in silencing plakoglobin gene expression
in ARMS cells, whose over-expression was shown to sup-
press tumorigenicity in different cancer cell lines [64].
Moreover, recent findings suggest that suppression of
BMP2 by epigenetic silencing may play a critical role in
the genesis of RMS [65]. Based on these findings, 5-aza-
dC might be a promising therapeutic agent in patients
with RMS. To date, azacytidine is FDA-approved for the
treatment of patients with acute myeloid leukemia and
myelodysplastic syndrome [66,67]. Data in sarcomas are
still limited [68], but ongoing clinical trials in the field of
epigenetic treatment suggest that this approach may be a
potential option for patients with sarcomas, including
RMS [69].
Conclusions
This study suggests that miR-378a-3p is involved in RMS
pathogenesis, exerting tumour suppressor-like activity.
Since miR-378a-3p is down-regulated in other malignan-
cies, the identification of the regulated tumorigenic path-
ways might have important implications in oncology. A
better understanding of the biological mechanisms under-
lying RMS development represents a fundamental step in
order to identify novel diagnostic and prognostic markers,
as well as to develop targeted therapies in children and ad-
olescents with RMS. Indeed, a combination of molecules
inhibiting IGF1R signalling and promoting demethylation
might be a possible therapeutic strategy worth to be fur-
ther investigated in this tumour.
Additional files
Additional file 1: Table S1. Expression of miR-378 family members in
RMS tumours. (A) miR-378 molecules differentially expressed in ARMs vs.
NMS, with NMS baseline. (B): miR-378 molecules differentially expressed
in ERMS vs. NMS, with NMS baseline. The members of the miR-378 family
have FC values always negative and significant in both comparisons,
indicating a strong under-expression in the investigated ARMS and
ERMS samples.
Additional file 2: Figure S1. Validation of miRNA array data by
quantitative real-time polymerase chain reaction (Q-PCR). (A) Relative
expression levels for miR-378a-3p, miR-378a-5p, miR-483-3p and miR-503-5p
in RMS patients (ARMS and ERMS collectively considered) in comparison to
NSM. Histograms indicate the mean value ± SD of independent samples
(ARMS1-2-3-4-7-36-37 and ERMS1-2-3-4-12-21-23-27); (B) Relative fold
change of miR-378a-3p, miR-378a-5p, miR-483-3p and miR-503-5p in RMS
cell lines in comparison to NSM. Histograms represent the mean value ± SD
of 4 different cell lines (RH4, RH30, RD and RD18). Y-axis values are expressed
as log2FC (**, p < 0.05; **p < 0.01).
Additional file 3: Table S2. Description of worksheet. Target Genes
Gene Annotation = > ENSEMBL annotation for miR-378a-3p target
genes. Target Genes GO Annotation = > ENSEMBL GO annotations for
miR-378a-3p target genes; cancer- and muscle- associated categories are
highlighted in blue. TGT Genes Reactome Enrichment = > analysis of overrepresentation of Reactome Pathways in the miR-378a-3p target genes.
TGT Genes DAVID Clustering = >most significant functional clusters from
a DAVID analysis of the miR-378a-3p target genes. TGT Genes FI Network
no linkers = > graphical representation and description of the Functional
Interactions associated with the network edges of a FI network analysis
performed on the miR-378a-3p target genes. No linker genes (functional
links not present in the original gene list) were considered in this analysis.
TGT Genes FI Network – Pathways = > pathway (CellMap, Reactome,
KEGG, NCI Panther and BioCarta) enrichment analysis of the FI network.
FI Network GO Enrichment = > Graphical representation and table of
the most significant results of a Network Ontology Analysis on the FI
network, keeping into account the functional links (edges) between the
network nodes. FI Network GO (Cellular Component, Biological Process,
Molecular Function) = > enrichment analysis, category by category, of the
GO annotation associated with the FI network. TGT Genes Clustered FI
Network = > cluster (module) analysis of the FI network, searching for
functional modules and associated pathway over representation. Clus-
tered FI Network + Linkers = > graphical representation and analysis of
the over represented pathways associated with the network edges of a
(clustered) FI network analysis performed on the miR-378a-3p target
genes. Linker genes (functional links not present in the original gene list)
were considered in this analysis, so as to give a broader view of the
functional significance of the identified target gene set.
Additional file 4: Figure S2. Levels of transfected miR-378a-3p mature
mimics in RMS cell lines. Relative expression of miR-378a-3p by Q-PCR at
72 h post transfection in RH30 and RD cells compared with miR-Ctr
transfected cells. Levels of miR-378a-5p were measured to confirm the
specificity of miR-378a-3p mimic transfection. Three independent
experiments were performed. Comparing with respective miR-Ctr,
**p < 0.01.
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